US6685941B1
(en)
*
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
IL92382A
(en)
*
|
1988-11-23 |
1994-12-29 |
Univ Michigan |
Use of a ligand specific for CD28 in the manufacture of medicament
|
US6406696B1
(en)
|
1989-10-27 |
2002-06-18 |
Tolerance Therapeutics, Inc. |
Methods of stimulating the immune system with anti-CD3 antibodies
|
JP2546544B2
(ja)
*
|
1989-10-27 |
1996-10-23 |
アーチ ディベラップメント コーポレイション |
免疫強化を促進するための方法と組成物
|
US6090914A
(en)
*
|
1991-06-27 |
2000-07-18 |
Bristol-Myers Squibb Company |
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
|
US5770197A
(en)
*
|
1991-06-27 |
1998-06-23 |
Bristol-Myers Squibb Company |
Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
|
US5637481A
(en)
*
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
US5851795A
(en)
*
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
CA2089229C
(en)
*
|
1992-02-14 |
2010-04-13 |
Alejandro A. Aruffo |
Cd40cr receptor and ligands therefor
|
US6472510B1
(en)
*
|
1992-02-14 |
2002-10-29 |
Bristol-Myers Squibb Company |
CD40 receptor ligands
|
CA2133075A1
(en)
*
|
1992-04-07 |
1993-10-14 |
Craig B. Thompson |
CD28 Pathway Immunoregulation
|
US5747034A
(en)
*
|
1992-07-09 |
1998-05-05 |
Chiron Corporation |
Methods and materials for the induction of T cell anergy
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US5773253A
(en)
*
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
US6024957A
(en)
*
|
1993-06-02 |
2000-02-15 |
Research Corporation Technologies, Inc. |
Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
|
US6106834A
(en)
|
1993-06-02 |
2000-08-22 |
Research Corporation Technologies, Inc. |
Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
|
JPH08506247A
(ja)
*
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えctla4ポリペプチドおよびその製造方法
|
US5861310A
(en)
*
|
1993-11-03 |
1999-01-19 |
Dana-Farber Cancer Institute |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
JPH09500788A
(ja)
|
1993-07-26 |
1997-01-28 |
ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド |
B7−2:ctla4/cd28カウンターレセプター
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
US6723705B1
(en)
|
1993-08-19 |
2004-04-20 |
Gentics Institute, Inc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6824779B1
(en)
|
1993-07-26 |
2004-11-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for inhibiting the interaction of B7-2 with its natural ligand
|
US20050129670A1
(en)
*
|
1993-07-26 |
2005-06-16 |
Genetics Institute, Llc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6130316A
(en)
*
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
AU7526894A
(en)
*
|
1993-08-16 |
1995-03-14 |
Arch Development Corporation |
B7-2: ctla4/cd28 counter receptor
|
AU7638894A
(en)
*
|
1993-09-03 |
1995-03-22 |
Miyuki Azuma |
B70(b7-2):ctla-4 bonding protein
|
AU784510B2
(en)
*
|
1994-03-08 |
2006-04-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for modulating T cell unresponsiveness
|
AU709711B2
(en)
*
|
1994-03-08 |
1999-09-02 |
Dana-Farber Cancer Institute |
Methods for modulating T cell unresponsiveness
|
US6719972B1
(en)
*
|
1994-06-03 |
2004-04-13 |
Repligen Corporation |
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
|
CA2204183A1
(en)
*
|
1994-11-01 |
1996-05-09 |
Andrew Lawrence Feldhaus |
Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
|
US5576423A
(en)
|
1994-12-02 |
1996-11-19 |
Schering Corporation |
Antibodies to the slam protein expressed on activated T cells
|
WO1996017060A1
(en)
*
|
1994-12-02 |
1996-06-06 |
Schering Corporation |
Purified genes encoding mammalian cell surface antigens; proteins and antibodies
|
US5872154A
(en)
*
|
1995-02-24 |
1999-02-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant adenovirus
|
US5652224A
(en)
|
1995-02-24 |
1997-07-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
WO1996031229A1
(en)
*
|
1995-04-05 |
1996-10-10 |
Beth Israel Hospital Association |
Inhibiting rejection of a graft
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US5811097A
(en)
*
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US5855887A
(en)
*
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
US6051227A
(en)
*
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US7041634B2
(en)
|
1995-09-27 |
2006-05-09 |
Emory University |
Method of inhibiting immune system destruction of transplanted viable cells
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
US6107056A
(en)
*
|
1996-02-22 |
2000-08-22 |
Oaks; Martin K. |
SCTLA-4 gene and product
|
AU710998B2
(en)
*
|
1996-03-20 |
1999-10-07 |
Bristol-Myers Squibb Company |
Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
|
US5786152A
(en)
*
|
1996-04-26 |
1998-07-28 |
Amgen Inc. |
Methods of inhibiting syp binding to a CTLA-4 receptor
|
CN1198646C
(zh)
*
|
1996-11-08 |
2005-04-27 |
生物基因Idec公司 |
抗体与人b7.1和b7.2之间独特结合相互作用的鉴定
|
US20060034844A1
(en)
*
|
1996-12-04 |
2006-02-16 |
The Regents Of The University Of California |
Stimulation of T cells against self antigens using CTLA-4 blocking agents
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
KR19980066046A
(ko)
*
|
1997-01-18 |
1998-10-15 |
정용훈 |
고역가의 CTLA4-Ig 융합단백질
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
ZA98533B
(en)
*
|
1997-01-31 |
1999-07-22 |
Bristol Myers Squibb Co |
Soluble CTLA4 mutant molecules and uses thereof.
|
WO1998042752A1
(en)
|
1997-03-21 |
1998-10-01 |
Brigham And Women's Hospital Inc. |
Immunotherapeutic ctla-4 binding peptides
|
SE9701127D0
(sv)
*
|
1997-03-26 |
1997-03-26 |
Karolinska Innovations Ab |
Antigenic fusionprotein carrying GALal, 3GAL epitopes
|
JP4382163B2
(ja)
*
|
1997-03-27 |
2009-12-09 |
ザ カウンシル オブ ザ クイーンズランド インスティチュート オブ メディカル リサーチ |
ターゲッティング分子を用いた免疫応答の増強
|
DK0975755T3
(da)
|
1997-04-16 |
2007-06-11 |
Millennium Pharm Inc |
CRSP-protein (cysteinrige udskilte proteiner), nukleinsyremolekyler der koder herfor samt anvendelser deraf
|
CA2293666A1
(en)
*
|
1997-06-12 |
1998-12-17 |
Applied Research Systems Ars Holding N.V. |
Cd28/ctla-4 inhibiting peptidomimetics, pharmaceutical compositions thereof, and method of using same
|
AU9095498A
(en)
*
|
1997-09-19 |
1999-04-12 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Oligopeptide compounds
|
US6955811B2
(en)
*
|
1997-11-07 |
2005-10-18 |
Trillium Therapeutics Inc. |
Methods of inhibiting immune response suppression by administering antibodies to OX-2
|
US7223729B2
(en)
*
|
1997-11-07 |
2007-05-29 |
Trillium Therapeutics Inc. |
Methods of treating allergy by administering a CD200 protein
|
ES2260852T3
(es)
*
|
1997-11-07 |
2006-11-01 |
Trillium Therapeutics Inc. |
Metodos y composiciones para inmunomodulacion.
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
EP1073465B1
(en)
*
|
1998-04-15 |
2005-06-22 |
The Brigham And Women's Hospital, Inc. |
T cell inhibitory receptor compositions and uses thereof
|
US7078512B2
(en)
|
1998-05-01 |
2006-07-18 |
Schering-Plough Animal Health Corporation |
Nucleic acid encoding feline CD86
|
US7279168B2
(en)
|
1998-05-01 |
2007-10-09 |
Texas A & M University System |
Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
|
US20050031611A1
(en)
*
|
1998-05-08 |
2005-02-10 |
Beth Israel Deaconess Medical Center |
Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
|
US6682741B1
(en)
|
1998-06-10 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
β2 microglobulin fusion proteins and high affinity variants
|
DE69933216T2
(de)
*
|
1998-06-15 |
2007-09-20 |
GTC Biotherapeutics, Inc., Framingham |
Erythropoietin-analog-menschliches serum-albumin fusionsprotein
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
US6593133B1
(en)
|
1998-07-06 |
2003-07-15 |
Nsgene A/S |
Neurotrophic factors
|
NZ511034A
(en)
|
1998-09-21 |
2004-03-26 |
American Nat Red Cross |
Methods of downmodulating the immune response to therapeutic proteins
|
US6800457B2
(en)
|
1998-09-22 |
2004-10-05 |
Bristol-Myers Squibb Company |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
US6521419B1
(en)
|
1998-09-22 |
2003-02-18 |
Kanakaraju Koduri |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
EP2112166B1
(en)
|
1998-12-23 |
2018-11-21 |
Pfizer Inc. |
Human monoclonal antibodies to ctla-4
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US7011833B1
(en)
|
1999-05-06 |
2006-03-14 |
Genetics Institute, Inc. |
Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
|
US6613327B1
(en)
|
1999-07-28 |
2003-09-02 |
Genetics Institute, Inc. |
Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
KR100996759B1
(ko)
|
1999-08-24 |
2010-11-25 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
DE60127933T2
(de)
*
|
2000-01-03 |
2008-02-07 |
Mark L. Merion Station Tykocinski |
Chimäre proteine und anwendungen
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
EP3029062A1
(en)
*
|
2000-05-26 |
2016-06-08 |
Bristol-Myers Squibb Company |
Soluble ctla4 mutant molecules and uses thereof
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
JP2004503507A
(ja)
*
|
2000-06-09 |
2004-02-05 |
ブリストル−マイヤーズ スクイブ カンパニー |
リンパ球シグナルのブロックおよびlfa−1媒介性接着のブロックによる細胞性免疫応答の調節方法
|
US20050048614A1
(en)
*
|
2000-06-13 |
2005-03-03 |
Children's Medical Center Corporation |
Biosynthetic oncolytic molecules and uses therefor
|
US20040034193A1
(en)
*
|
2001-06-13 |
2004-02-19 |
Samy Ashkar |
Biosynthetic oncolytic molecules and uses therefor
|
KR100864120B1
(ko)
|
2000-07-03 |
2008-10-16 |
브리스톨-마이어스스퀴브컴파니 |
가용성 ctla4 분자를 사용한 류마티스성 질환의 치료법
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
US6875904B2
(en)
*
|
2000-09-20 |
2005-04-05 |
The Ohio State University Research Foundation |
Animal model for identifying agents that inhibit or enhance CTLA4 signaling
|
US7014998B2
(en)
*
|
2000-09-30 |
2006-03-21 |
Yale University |
Screening immunomodulatory agents by CTLA-4 upregulation
|
JP4280803B2
(ja)
*
|
2000-12-08 |
2009-06-17 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
慢性リンパ性白血病細胞株および抗体を産生するためのその使用
|
US7408041B2
(en)
*
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
AU2002243905B2
(en)
*
|
2001-01-26 |
2007-11-08 |
Emory University |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
JP4499362B2
(ja)
|
2001-03-28 |
2010-07-07 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ニューロパシーの疼痛を処置するためのニューブラスチンポリペプチドの使用
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
PT1397153E
(pt)
|
2001-05-23 |
2008-06-12 |
Bristol Myers Squibb Co |
Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US20030086940A1
(en)
*
|
2001-08-10 |
2003-05-08 |
Cristina Costa |
Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
|
US20040116675A1
(en)
*
|
2001-12-14 |
2004-06-17 |
Tso J. Jun |
Silenced anti-cd28 antibodies and use thereof
|
CA2471777A1
(en)
*
|
2001-12-18 |
2003-06-26 |
Endocube Sas |
Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
|
US7858297B2
(en)
*
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
WO2003070823A2
(en)
|
2002-02-20 |
2003-08-28 |
The General Hospital Corporation |
Conjugates comprising a biodegradable polymer and uses therefor
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
CN1652820A
(zh)
*
|
2002-04-12 |
2005-08-10 |
梅达雷克斯公司 |
使用ctla-4抗体的治疗方法
|
US20060093612A1
(en)
*
|
2002-05-02 |
2006-05-04 |
Srivastava Pramod K |
Use of heat shock proteins to enhance efficacy of antibody therapeutics
|
WO2004034995A2
(en)
*
|
2002-10-15 |
2004-04-29 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Methods and reagents for inducing immunity
|
AU2003303394B2
(en)
*
|
2002-12-23 |
2009-02-19 |
Bristol-Myers Squibb Company |
Product quality enhancement in mammalian cell culture processes for protein production
|
TWI312368B
(en)
*
|
2002-12-23 |
2009-07-21 |
Bristol Myers Squibb Compan |
Mammalian cell culture processes for protein production
|
KR101293805B1
(ko)
|
2003-01-31 |
2013-08-06 |
바이오겐 아이덱 엠에이 인코포레이티드 |
돌연변이된 뉴블라스틴의 중합체 컨주게이트
|
GB0303663D0
(en)
*
|
2003-02-18 |
2003-03-19 |
Lorantis Ltd |
Assays and medical treatments
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
US6971600B2
(en)
*
|
2003-06-30 |
2005-12-06 |
Heligear Engineering (H.K.) Co., Ltd. |
Oscillation mechanism for fishing reel
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
CA2762015A1
(en)
*
|
2003-08-04 |
2005-02-24 |
Bristol-Myers Squibb Company |
Methods for treating cardiovascular disease using a soluble ctla4 molecule
|
AU2004287431B2
(en)
*
|
2003-10-27 |
2010-03-11 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
EP1793858A4
(en)
*
|
2004-09-08 |
2008-12-10 |
Univ Ohio State Res Found |
HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
|
US20080152655A1
(en)
*
|
2004-09-08 |
2008-06-26 |
The Ohio State University Research Foundation |
Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
|
GB0421465D0
(en)
*
|
2004-09-27 |
2004-10-27 |
Chiron Srl |
Group A streptococcus protein
|
WO2006108035A1
(en)
*
|
2005-04-06 |
2006-10-12 |
Bristol-Myers Squibb Company |
Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
|
US8663634B2
(en)
|
2005-07-11 |
2014-03-04 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
PL1912675T3
(pl)
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
JP4899083B2
(ja)
*
|
2005-08-29 |
2012-03-21 |
Smc株式会社 |
減速比自動切換装置
|
US20070111962A1
(en)
*
|
2005-11-08 |
2007-05-17 |
Mourich Dan V |
Immunosuppression compound and treatment method
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
AU2013202533B2
(en)
*
|
2005-11-08 |
2015-11-12 |
Sarepta Therapeutics, Inc. |
Immunosuppression Compound and Treatment Method
|
NZ568016A
(en)
|
2005-12-07 |
2011-12-22 |
Medarex Inc |
CTLA-4 antibody dosage escalation regimens
|
US10508144B2
(en)
|
2005-12-20 |
2019-12-17 |
Bristol-Myers Squibb Company |
Carbohydrate content of CTLA4 molecules
|
HUE028179T2
(en)
|
2006-01-12 |
2016-12-28 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and their use
|
JP2009531324A
(ja)
|
2006-03-20 |
2009-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体
|
US7528111B2
(en)
*
|
2006-05-12 |
2009-05-05 |
Bristol-Myers Squibb Company |
Method of vaccinating subjects receiving immune modulating therapy
|
NZ596865A
(en)
|
2006-06-12 |
2013-07-26 |
Emergent Product Dev Seattle |
Single-chain multivalent binding proteins with effector function
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
CA2694121C
(en)
*
|
2007-07-25 |
2016-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune disease
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
EP2385065A1
(en)
|
2007-11-01 |
2011-11-09 |
Perseid Therapeutics LLC |
Immunosuppressive polypeptides and nucleic acids
|
CN102099377A
(zh)
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
US7915222B2
(en)
*
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
CN102227447A
(zh)
|
2008-10-02 |
2011-10-26 |
新兴产品开发西雅图有限公司 |
Cd86拮抗物多靶点结合蛋白
|
CN102271708A
(zh)
*
|
2008-11-13 |
2011-12-07 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗联合疗法及其用途
|
JP5883384B2
(ja)
*
|
2009-08-13 |
2016-03-15 |
ザ ジョンズ ホプキンス ユニバーシティー |
免疫機能を調節する方法
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
BR112012008665A2
(pt)
|
2009-10-12 |
2016-11-22 |
Pfizer |
tratamento de câncer
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
CN103153332A
(zh)
|
2010-09-28 |
2013-06-12 |
卡尔医疗有限公司 |
用于治疗血液恶性肿瘤的组合物和方法
|
WO2013010537A1
(en)
|
2011-07-20 |
2013-01-24 |
Aarhus Universitet |
Method of treating morphea
|
WO2013148049A1
(en)
|
2012-03-29 |
2013-10-03 |
The General Hospital Corporation |
Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
WO2013169338A1
(en)
|
2012-05-11 |
2013-11-14 |
Medimmune, Llc |
Ctla-4 variants
|
US8735359B2
(en)
|
2012-05-24 |
2014-05-27 |
Orban Biotech Llc |
Combinations of modalities for the treatment of diabetes
|
EP2866823A4
(en)
|
2012-06-27 |
2016-03-02 |
Orban Biotech Llc |
CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
|
US20140112958A1
(en)
|
2012-10-24 |
2014-04-24 |
Mwm Biomodels Gmbh |
Pancreatic islets of transgenic LEA29Y animals for treating diabetes
|
WO2014138188A1
(en)
|
2013-03-07 |
2014-09-12 |
The General Hospital Corporation |
Human ctla4 mutants and use thereof
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
GB2523399B
(en)
|
2014-02-25 |
2019-03-13 |
Orban Tihamer |
A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
|
US11344620B2
(en)
|
2014-09-13 |
2022-05-31 |
Novartis Ag |
Combination therapies
|
CA2972757A1
(en)
|
2014-12-31 |
2016-07-07 |
Arthur M. Krieg |
Combination tumor immunotherapy
|
CN114773486A
(zh)
|
2015-04-17 |
2022-07-22 |
高山免疫科学股份有限公司 |
具有可调的亲和力的免疫调节蛋白
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
EP3192805A1
(en)
|
2016-01-15 |
2017-07-19 |
Humanitas Mirasole S.p.A. |
Inhibitors of t cell activation or stimulation and uses thereof
|
SG11201907867TA
(en)
|
2017-02-28 |
2019-09-27 |
Bristol Myers Squibb Co |
Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
JP2020536552A
(ja)
|
2017-10-10 |
2020-12-17 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ctla−4変異型免疫調節タンパク質およびそれらの使用
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
EP3886759A1
(en)
|
2018-11-26 |
2021-10-06 |
Massachusetts Institute of Technology |
Compositions and methods for immune tolerance
|
WO2021102437A1
(en)
|
2019-11-21 |
2021-05-27 |
Bristol-Myers Squibb Company |
Label-free n-glycan quantification methods
|
AU2022224584A1
(en)
|
2021-02-19 |
2023-09-21 |
Theripion, Inc. |
Paraoxonase fusion polypeptides and related compositions and methods
|
GB202115803D0
(en)
|
2021-11-03 |
2021-12-15 |
Ducentis Biotherapeutics Ltd |
Novel proteins
|
WO2023214388A1
(en)
|
2022-05-06 |
2023-11-09 |
Ducentis Biotherapeutics Limited |
Novel cd200 fusion proteins
|
WO2023214387A1
(en)
|
2022-05-06 |
2023-11-09 |
Ducentis Biotherapeutics Limited |
Novel cd200 fusion proteins
|
CN114686427B
(zh)
*
|
2022-05-23 |
2022-07-29 |
中国人民解放军总医院第一医学中心 |
一种脾脏调节型b淋巴细胞及其制备方法与应用
|